AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday May 21, 2025. Kave Niksefat senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , YouTube and Threads .

CONTACT: Amgen, Thousand Oaks
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (investors)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-the-2025-rbc-capital-markets-global-healthcare-conference-302458021.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

(TheNewswire) Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ Kelowna, British Columbia - June 9, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery... Keep Reading...
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing... Keep Reading...
Doctor holds tablet displaying digital human body with health data, overlaid with medical icons.

Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer

Metastatic breast cancer (MBC) remains incurable, with approximately only one-third of diagnosed women meeting the five year survival rate.Subtypes like triple-negative breast cancer (TNBC) or heavily pretreated hormone receptor-positive disease often come with more treatment challenges, leading... Keep Reading...
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance... Keep Reading...
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2026

The biotech sector has made significant strides in recent years, and the market's volatility can increase the appeal of biotech ETFs. Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded... Keep Reading...
Doctor holding stethoscope over digital document interface

Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing

Nature Medicine’s “Eleven Clinical Trials That Will Shape Medicine in 2026” highlights studies poised to influence patient care. Among the oncology selections, BriaCell Therapeutics' (TSX:BCT,NASDAQ:BCTX) pivotal Phase 3 trial of Bria-IMT™ stands out as a rare entry. This feature underscores the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News